 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- ||||| Remedisc (SB-01) / Spine Biopharma
Enrollment closed: MODEL: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine (clinicaltrials.gov) - Sep 26, 2024
P3, N=417, Active, not recruiting, Sponsor: Spine BioPharma, Inc
Recruiting --> Active, not recruiting
- |||| Remedisc (SB-01) / Spine Biopharma
Trial completion date, Trial primary completion date: MODEL: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine (clinicaltrials.gov) - Dec 5, 2023
P3, N=400, Recruiting, Sponsor: Spine BioPharma, Inc
Recruiting --> Active, not recruiting Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Remedisc (SB-01) / Spine Biopharma
New P3 trial: MODEL: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine (clinicaltrials.gov) - Aug 26, 2022
P3, N=400, Recruiting, Sponsor: Spine BioPharma, Inc
- |||| Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Trial completion: Clinical Trial of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Nov 10, 2016
P2b, N=326, Completed, Sponsor: Yuhan Corporation
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed
- | Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Phase classification: Clinical Trial of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Jun 10, 2016
P2b, N=326, Active, not recruiting, Sponsor: Yuhan Corporation
Active, not recruiting --> Completed Phase classification: P2 --> P2b
- ||| Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Enrollment closed: Clinical Trial of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Feb 22, 2016
P2, N=324, Active, not recruiting, Sponsor: Yuhan Corporation
Phase classification: P2 --> P2b Recruiting --> Active, not recruiting
- || Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Trial primary completion date: Clinical Trial of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Jan 17, 2016
P2, N=320, Recruiting, Sponsor: Yuhan Corporation
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Apr 2016
- |||| Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Enrollment open: Clinical Trial of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - May 22, 2015
P2, N=320, Recruiting, Sponsor: Yuhan Corporation
Trial primary completion date: Dec 2016 --> Apr 2016 Not yet recruiting --> Recruiting
- | Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Trial completion: Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=48, Completed, Sponsor: Yuhan Corporation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
New P2 trial: Clinical Trial of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Dec 19, 2014
P2, N=320, Not yet recruiting, Sponsor: Yuhan Corporation
- | Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
Enrollment closed: Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Dec 30, 2013
P1/2, N=48, Active, not recruiting, Sponsor: Yuhan Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Remedisc (SB-01) / Yuhan Corp, Spine Biopharma
New P1/2 trial: Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease (clinicaltrials.gov) - Feb 1, 2012
P1/2, N=48, Active, not recruiting, Sponsor: Yuhan Corporation